SG11201405239WA - Thiazole derivatives as alpha 7 nachr modulators - Google Patents

Thiazole derivatives as alpha 7 nachr modulators

Info

Publication number
SG11201405239WA
SG11201405239WA SG11201405239WA SG11201405239WA SG11201405239WA SG 11201405239W A SG11201405239W A SG 11201405239WA SG 11201405239W A SG11201405239W A SG 11201405239WA SG 11201405239W A SG11201405239W A SG 11201405239WA SG 11201405239W A SG11201405239W A SG 11201405239WA
Authority
SG
Singapore
Prior art keywords
alpha
thiazole derivatives
nachr modulators
nachr
modulators
Prior art date
Application number
SG11201405239WA
Inventor
Neelima Sinha
Navnath Popat Karche
Anil Kashiram Hajare
Shridhar Keshav Adurkar
Bikramjit Singh Lairikyengbam
Firoj Aftab Raje
Ajay Ramchandra Tilekar
Baban Rupaji Thube
Venkata P Palle
Rajender Kumar Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SG11201405239WA publication Critical patent/SG11201405239WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201405239WA 2012-03-06 2013-02-22 Thiazole derivatives as alpha 7 nachr modulators SG11201405239WA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN237KO2012 2012-03-06
IN236KO2012 2012-03-06
IN235KO2012 2012-03-06
IN1307KO2012 2012-11-12
PCT/IB2013/051455 WO2013132380A1 (en) 2012-03-06 2013-02-22 Thiazole derivatives as alpha 7 nachr modulators

Publications (1)

Publication Number Publication Date
SG11201405239WA true SG11201405239WA (en) 2014-09-26

Family

ID=54261190

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201405239WA SG11201405239WA (en) 2012-03-06 2013-02-22 Thiazole derivatives as alpha 7 nachr modulators

Country Status (8)

Country Link
US (1) US9388196B2 (en)
EP (1) EP2822946A1 (en)
AU (1) AU2013229177B2 (en)
CA (1) CA2866015A1 (en)
IN (1) IN2014MN01756A (en)
NZ (1) NZ629453A (en)
SG (1) SG11201405239WA (en)
WO (1) WO2013132380A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117913C2 (en) * 2012-05-31 2018-10-25 Фінекс Фармас'Ютікалс Аг Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
WO2014072957A1 (en) * 2012-11-12 2014-05-15 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
WO2014141091A1 (en) 2013-03-13 2014-09-18 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
TW201446243A (en) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator
CA2913987A1 (en) 2013-06-17 2014-12-24 Lupin Limited Pyrrole derivatives as alpha 7 nachr modulators
US9902719B2 (en) 2014-07-03 2018-02-27 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
JP6612874B2 (en) 2014-12-16 2019-11-27 アクソファント サイエンシーズ ゲーエムベーハー Geminal-substituted quinuclidineamide compounds as agonists of α7-nicotinic acetylcholine receptors
MX2017016231A (en) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
EP3325473A4 (en) 2015-07-22 2019-06-26 The Royal Institution for the Advancement of Learning / McGill University Compounds and uses thereof in the treatment of cancers and other medical conditions
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CN108101860B (en) * 2018-02-08 2021-11-23 苏州敬业医药化工有限公司 Preparation method of cis-2, 6-dimethyl morpholine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953596A (en) 1973-06-14 1976-04-27 Ici United States Inc. 8-Oxa-3-azabicyclo(3.2.1)octane analgesic compositions and method of alleviating pain in animals
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1996003392A1 (en) * 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
EP1012142B1 (en) 1997-09-12 2004-08-11 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
BR0307409A (en) 2002-02-01 2004-12-28 Dainippon Pharmaceutical Co 2-Furanecarboxylic acid hydrazide compounds, pharmaceutical compositions containing them and use thereof for the preparation of a preventive or therapeutic agent
US7202367B2 (en) 2002-05-31 2007-04-10 Rhodia Chimie Process for arylating or vinylating or alkynating a nucleophilic compound
SE0201938D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New process
DE10244810A1 (en) 2002-09-26 2004-04-08 Bayer Ag New morpholine-bridged indazole derivatives
US7129235B2 (en) 2003-07-11 2006-10-31 Abbott Laboratories Amides useful for treating pain
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
RU2006131454A (en) 2004-03-29 2008-05-10 Ньюросерч А/С (DK) NEW UREA DERIVATIVES AND THEIR MEDICAL USE
ITTO20040264A1 (en) 2004-04-28 2004-07-28 Rotta Res Lab Spa NEW PYROLIC DERIVATIVES WITH ANGIOTENSIN-II ANTAGONIST ACTIVITY
TW200621723A (en) 2004-09-09 2006-07-01 Chugai Pharmaceutical Co Ltd Novel imidazolidine derivative and use thereof
US20060142349A1 (en) 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
DE602006016926D1 (en) 2005-02-16 2010-10-28 Neurosearch As NEW DIAZABICYCLIC ARYL DERIVATIVES AND MEDICAL USE THEREOF
FR2885616B1 (en) 2005-05-12 2007-06-22 Servier Lab NOVEL PHENYLPYRIDINYLPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2617788A1 (en) 2005-08-04 2007-02-15 Apogee Biotechnology Corporation Sphingosine kinase inhibitors and methods of their use
WO2007031440A2 (en) 2005-09-13 2007-03-22 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
ES2452031T3 (en) 2006-02-03 2014-03-31 Eli Lilly & Company Compounds and procedures to modulate FX receivers
EP1987029B1 (en) 2006-02-16 2010-01-13 Neurosearch A/S Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands
JO3019B1 (en) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-Triazoles
US7741364B2 (en) 2006-06-27 2010-06-22 Abbott Laboratories Pyrrole derivatives and their methods of use
US7683084B2 (en) 2006-06-27 2010-03-23 Abbott Laboratories Thiazoline and oxazoline derivatives and their methods of use
US20100069347A1 (en) 2006-11-02 2010-03-18 Morriello Gregori J Heterocyclyl-substituted anti-hypercholesterolemic compounds
US20080287479A1 (en) 2006-12-20 2008-11-20 Pfizer Inc Inhibitors of serine palmitoyltransferase
EP2185529A1 (en) 2007-08-08 2010-05-19 NeuroSearch AS Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0718735D0 (en) 2007-09-25 2007-11-07 Prolysis Ltd Antibacterial agents
CN101821246B (en) 2007-10-04 2013-05-01 弗·哈夫曼-拉罗切有限公司 Tetrazole-substituted arylamide derivatives and uses thereof
AU2008307195B2 (en) 2007-10-04 2012-11-22 F. Hoffmann-La Roche Ag Cyclopropyl aryl amide derivatives and uses thereof
JO2784B1 (en) 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 1,3,5-trisubstitued triazole derivative
KR101564303B1 (en) 2008-03-19 2015-11-06 얀센 파마슈티카 엔.브이. Trisubstituted 1,2,4-triazoles as nicotinic acetylcholine receptor modulators
US7786171B2 (en) 2008-04-04 2010-08-31 Abbott Laboratories Amide derivatives as positive allosteric modulators and methods of use thereof
EP2279183B1 (en) 2008-04-17 2012-08-08 Proximagen Limited Indoles as modulators of nicoticic acetylcholine receptor subtype alpha-7
CL2009001125A1 (en) 2008-05-09 2011-02-11 Janssen Pharmaceutica Nv Compounds derived from trisubstituted pyrazole, positive allosteric modulators of ach nicotinic receptors; pharmaceutical composition that includes them; composition preparation process; and its use in the treatment of CNS or inflammatory diseases.
EP2387575B1 (en) 2009-01-15 2013-09-04 Anvyl, LLC Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
WO2010120854A1 (en) 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
WO2010130768A1 (en) 2009-05-14 2010-11-18 Neurosearch A/S Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators
JO3250B1 (en) 2009-09-22 2018-09-16 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
JO3078B1 (en) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv Morpholinothiazoles as alpha 7 positive allosteric modulators
MX344701B (en) 2011-02-03 2017-01-03 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr.
MA34957B1 (en) 2011-02-23 2014-03-01 Lupin Ltd HETEROARYL DERIVATIVES AS MODULATORS OF NACHR ALPHA 7
US9187420B2 (en) 2011-03-31 2015-11-17 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
ES2606043T3 (en) 2011-07-05 2017-03-17 Lupin Limited Biaryl derivatives as nAChR modulators

Also Published As

Publication number Publication date
AU2013229177A1 (en) 2014-09-18
WO2013132380A1 (en) 2013-09-12
NZ629453A (en) 2016-04-29
US9388196B2 (en) 2016-07-12
US20150291617A1 (en) 2015-10-15
CA2866015A1 (en) 2013-09-12
IN2014MN01756A (en) 2015-07-03
EP2822946A1 (en) 2015-01-14
AU2013229177B2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
HK1244781A1 (en) Aryl sultam derivatives as rorc modulators
SG11201405239WA (en) Thiazole derivatives as alpha 7 nachr modulators
HK1210709A1 (en) Composition for external use
EP2921510A4 (en) Surface treatment composition
ZA201503713B (en) Pyrrole derivatives as alpha 7 nachr modulators
HK1223933A1 (en) Keto-imidazopyridine derivatives as rorc modulators rorc -
EP2812190A4 (en) Surface treatment composition
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
TWM432338U (en) M1010701_3919
TWM432495U (en) M1010701_3919
TWM432299U (en) M1010701_3919
TWM432584U (en) M1010701_3919
TWM432411U (en) M1010701_3919
TWM432598U (en) M1010701_3919
TWM432248U (en) M1010701_3919
TWM432309U (en) M1010701_3919
TWM432296U (en) M1010701_3919
TWM432298U (en) M1010701_3919
TWM432582U (en) M1010701_3919
TWM432520U (en) M1010701_3919
TWM432312U (en) M1010701_3919
TWM432364U (en) M1010701_3919
TWM432311U (en) M1010701_3919
TWM432615U (en) M1010701_3919
TWM432356U (en) M1010701_3919